TCIM
PBYI icon

TIAA CREF Investment Management’s Puma Biotechnology PBYI Stock Holding History

TIAA CREF Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$5.49M Buy
141,641
+13,024
+10% +$398K ﹤0.01% 1379
2018
Q4 		$2.62M Sell
128,617
-36,019
-22% -$1.08M ﹤0.01% 1800
2018
Q3 		$7.55M Buy
164,636
+99,878
+154% +$4.82M ﹤0.01% 1289
2018
Q2 		$3.83M Sell
64,758
-5,293
-8% -$307K ﹤0.01% 1791
2018
Q1 		$4.77M Sell
70,051
-47,020
-40% -$3.52M ﹤0.01% 1579
2017
Q4 		$11.6M Sell
117,071
-12,735
-10% -$1.43M 0.01% 1052
2017
Q3 		$15.5M Buy
129,806
+6,692
+5% +$622K 0.01% 885
2017
Q2 		$10.8M Buy
123,114
+27,230
+28% +$1.52M 0.01% 1081
2017
Q1 		$3.57M Sell
95,884
-14,113
-13% -$515K ﹤0.01% 1793
2016
Q4 		$3.38M Buy
109,997
+26,445
+32% +$1.14M ﹤0.01% 1883
2016
Q3 		$5.6M Buy
83,552
+4,321
+5% +$218K ﹤0.01% 1532
2016
Q2 		$2.36M Buy
79,231
+5,423
+7% +$170K ﹤0.01% 2014
2016
Q1 		$2.17M Buy
73,808
+609
+0.8% +$27.5K ﹤0.01% 2021
2015
Q4 		$5.74M Sell
73,199
-8,102
-10% -$636K ﹤0.01% 1470
2015
Q3 		$6.13M Sell
81,301
-10,542
-11% -$997K ﹤0.01% 1399
2015
Q2 		$10.7M Sell
91,843
-13,343
-13% -$2.42M 0.01% 1105
2015
Q1 		$24.8M Buy
105,186
+923
+0.9% +$197K 0.02% 706
2014
Q4 		$19.7M Sell
104,263
-4,381
-4% -$972K 0.01% 779
2014
Q3 		$25.9M Sell
108,644
-2,594
-2% -$533K 0.02% 679
2014
Q2 		$7.34M Buy
111,238
+2,153
+2% +$153K 0.01% 1394
2014
Q1 		$11.4M Sell
109,085
-2,229
-2% -$262K 0.01% 1058
2013
Q4 		$11.5M Sell
111,314
-452
-0.4% -$26.5K 0.01% 1066
2013
Q3 		$6M Sell
111,766
-530
-0.5% -$28.6K ﹤0.01% 1448
2013
Q2 		$4.98M Buy
+112,296
New +$3.96M ﹤0.01% 1523

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

TIAA CREF Investment Management's PBYI Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Puma Biotechnology (PBYI) stake by 10% in Q1 2019, buying an estimated $398K and bringing the position to 141,641 shares worth $5.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

TIAA CREF Investment Management first reported a position in PBYI in Q2 2013 and has held it in 24 quarters since. The position peaked at $25.9M in Q3 2014. 158 funds tracked by Wall St. Rank hold PBYI as of Q1 2019.

  • TIAA CREF Investment Management held 141,641 shares of Puma Biotechnology worth $5.49M as of Q1 2019.
  • TIAA CREF Investment Management bought 13,024 Puma Biotechnology shares in Q1 2019, an estimated $398K.
  • Puma Biotechnology made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1379 holding.
  • TIAA CREF Investment Management first reported a position in Puma Biotechnology in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Puma Biotechnology position peaked at $25.9M in Q3 2014.
  • 158 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.